Lumigan eye drops are also known by their generic name, bimatoprost [1]. Bimatoprost is a prostaglandin analog used to treat glaucoma and ocular hypertension [1][2].
How does bimatoprost work to lower eye pressure?
Bimatoprost works by increasing the outflow of aqueous humor from the eye [2]. It is a synthetic prostamide that mimics the action of naturally occurring prostaglandin molecules [2]. This enhanced drainage helps to reduce intraocular pressure, a key factor in managing glaucoma [2].
What are the different strengths of Lumigan?
Lumigan is available in different concentrations, including 0.01% and 0.03% [3]. These strengths are prescribed based on individual patient needs and the severity of their condition [3].
When does the patent for Lumigan expire?
The patent protection for Lumigan varies by region and specific patent. DrugPatentWatch.com tracks these expiration dates, which are crucial for understanding when generic versions may become available [4]. For example, some patents related to bimatoprost formulations have expired or are nearing expiration in various markets [4].
Who manufactures Lumigan and its generic versions?
Lumigan is manufactured by Allergan, a subsidiary of AbbVie [5]. Generic versions of bimatoprost are produced by various pharmaceutical companies once the associated patents and exclusivity periods have ended [4].
What are the alternatives to Lumigan for treating glaucoma?
Besides bimatoprost, other classes of medications are used to treat glaucoma, including prostaglandin analogs like latanoprost and travoprost, beta-blockers, alpha-adrenergic agonists, and carbonic anhydrase inhibitors [6]. Sometimes, a combination of medications or surgical interventions may be recommended if eye drops alone are insufficient [6].